Sun Pharmaceutical Industries fell 10.30% to Rs 383.15 at 11:09 IST on BSE after media report of a complaint by a whistleblower raised fresh concerns on the drugmaker's corporate governance.
Meanwhile, the S&P BSE Sensex was down 44.06 points, or 0.12% to 36,330.02.On the BSE, 22.79 lakh shares were traded in the counter so far compared with average daily volumes of 4.45 lakh shares in the past two weeks. The stock had hit a high of Rs 425.50 and a low of Rs 375.40 so far during the day. The stock hit a 52-week high of Rs 678.80 on 6 September 2018. The stock hit a 52-week low of Rs 375.40 on 18 January 2019.
According to a media report, between 2014 and 2017, Aditya Medisales (AML) had over Rs 5,800 crore of transactions with Suraksha Realty, controlled by Sun Pharma's co-promoter, Sudhir Valia. This is according to a new 172-page complaint (with documents) sent by the whistleblower on Sun Pharma to the market regulator, Securities and Exchange Board of India (Sebi).
In December 2018, the first complaint by whistleblower alleged that Dilip Shanghvi, his brother-in-law Sudhir Valia were part of financial irregularities with Dharmesh Doshi. Doshi was allegedly a key figure in Ketan Parekh scam of 2001.
On a consolidated basis, Sun Pharmaceutical Industries reported net loss of Rs 108.84 crore in Q2 September 2018 compared with net profit of Rs 1001.79 crore in Q2 September 2017. Net sales rose 3.89% to Rs 6846.48 crore in Q2 September 2018 over Q2 September 2017.
Sun Pharmaceutical Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
